These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10087580)

  • 1. Bisphosphonates in clinical oncology. The development of pamidronate.
    Thürlmann B
    Recent Results Cancer Res; 1999; 149():1-113. PubMed ID: 10087580
    [No Abstract]   [Full Text] [Related]  

  • 2. [Is pamidronate or clodronate better?].
    Adam Z
    Vnitr Lek; 2002 Apr; 48(4):357. PubMed ID: 12075601
    [No Abstract]   [Full Text] [Related]  

  • 3. Bisphosphonates spearhead new approach to treating bone metastases.
    Bankhead C
    J Natl Cancer Inst; 1997 Jan; 89(2):115-6. PubMed ID: 8998176
    [No Abstract]   [Full Text] [Related]  

  • 4. Aredia: the once-monthly infusion for the treatment of bone metastases.
    Lipton A
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S1-5. PubMed ID: 9801852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of bisphosphonates in breast cancer.
    Coleman RE
    Breast; 2004 Dec; 13 Suppl 1():S19-28. PubMed ID: 15585379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fitting new modalities into practice guidelines.
    Theriault RL
    Oncology (Williston Park); 1997 Nov; 11(11A):145-9. PubMed ID: 9430184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bisphosphonates in the therapy of cancer patients].
    Jantunen E; Kumpulainen E
    Duodecim; 1999; 115(1):27-32. PubMed ID: 11830857
    [No Abstract]   [Full Text] [Related]  

  • 8. Bone targeted therapy in breast cancer: present and future.
    Huober J; Thürlimann B
    Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S7-10. PubMed ID: 20427030
    [No Abstract]   [Full Text] [Related]  

  • 9. Pamidronate and metastatic breast cancer.
    Rubiales AS; Centeno C
    N Engl J Med; 1997 May; 336(22):1609-10; author reply 1610. PubMed ID: 9173262
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
    Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
    Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates in breast cancer: antitumor effects.
    Aft R
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):292-9. PubMed ID: 21558988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role for bisphosphonates in cancer management.
    Chlebowski RT
    Breast Dis; 2011; 33(2):55-7. PubMed ID: 22142659
    [No Abstract]   [Full Text] [Related]  

  • 13. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates.
    Joerger M; Templeton A; Köberle D; Engler H; Riesen WF; Thürlimann B
    Cancer Chemother Pharmacol; 2011 May; 67(5):1137-44. PubMed ID: 20683595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
    Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
    N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Retardation of progression of bone metastasis in mammary carcinoma patients by intravenous pamidronate treatment: results of a randomized, controlled, multinational study].
    Adamietz IA
    Strahlenther Onkol; 1998 Aug; 174(8):438. PubMed ID: 9739387
    [No Abstract]   [Full Text] [Related]  

  • 16. [Bisphosphonates in the treatment of breast carcinoma].
    Stajszczyk M; Mykała-Cieśla J
    Pol Arch Med Wewn; 2001 Aug; 106(2):729-38. PubMed ID: 11926150
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pamidronate therapy for lung cancer patients with bone metastasis].
    Oura S; Yoshimasu T; Sakurai T; Nakamura T; Kokawa Y; Matsuyama K; Ohta F; Naito Y
    Gan To Kagaku Ryoho; 2000 Jul; 27(7):1057-60. PubMed ID: 10925695
    [No Abstract]   [Full Text] [Related]  

  • 18. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates in breast cancer patients with skeletal metastases.
    Shapiro CL
    Hematol Oncol Clin North Am; 1994 Feb; 8(1):153-63. PubMed ID: 8150777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A remarkable improvement of clinical manifestations in a breast cancer patient with widespread bone metastases after administration of pamidronate.
    Kage K; Nagahama T; Sekine I; Maruyama M; Ogata E
    Intern Med; 1997 Dec; 36(12):926-30. PubMed ID: 9475253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.